Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

MYC-stery of Down syndrome unraveled

Jan-Henning Klusmann

Blood (2024) 143 (25): 2566–2567.

https://doi.org/10.1182/blood.2024024595

Published: 2024

Journal Articles

TRIP13 Is a Fetal-Enriched Therapeutic Target in NUP98-JARID1A + Pediatric Non-Down Syndrome AMKL

Luca Nunzio Cifarelli, Hasan Issa, Konstantin Schuschel, Katja Menge, Lucie Gack, Christian Ihling, Andrea Sinz, Jan-Henning Klusmann, Dirk Heckl

Blood (2023) 142 (Supplement 1): 711.

https://doi.org/10.1182/blood-2023-182843

Published: 2023

Journal Articles

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Blood (2023) 142 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2023-188892

Published: 2023

Journal Articles

Double trouble: IRAK1/4 inhibitors in AML/MDS

Hannah J. Uckelmann, Jan-Henning Klusmann

Blood (2023) 142 (11): 945–946.

https://doi.org/10.1182/blood.2023020812

Published: 2023

Journal Articles

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Blood (2023) 141 (10): 1105–1118.

https://doi.org/10.1182/blood.2022017619

Published: 2023

Includes: Supplemental data

Journal Articles

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 6224–6225.

https://doi.org/10.1182/blood-2022-157833

Published: 2022

Journal Articles

CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML

Nawid Albinger, Tobias Bexte, Leon Buchinger, Philipp Wendel, Ahmad Al-Ajami, Alec Gessner, Vinzenz Särchen, Jamal Alzubi, Sarah Mertlitz, Olaf Penack, Raj Bhayadia, Jan-Henning Klusmann, Meike Vogler, Nina Möker, Toni Cathomen, Michael A. Rieger, Katharina Imkeller, Evelyn Ullrich

Blood (2022) 140 (Supplement 1): 4558–4559.

https://doi.org/10.1182/blood-2022-169758

Published: 2022

Journal Articles

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

Oriol Alejo-Valle, Karoline Weigert, Raj Bhayadia, Michelle Ng, Hasan Issa, Christoph Beyer, Stephan Emmrich, Konstantin Schuschel, Christian Ihling, Andrea Sinz, Martin Zimmermann, Claudia Wickenhauser, Marius Flasinski, Eniko Regenyi, Maurice Labuhn, Dirk Reinhardt, Marie-Laure Yaspo, Dirk Heckl, Jan-Henning Klusmann

Blood (2022) 139 (5): 651–665.

https://doi.org/10.1182/blood.2021012231

Published: 2022

Includes: Supplemental data

Journal Articles

Myeloid Leukemia Dependencies at CTCF-Enriched Long Noncoding RNA Loci

Michelle Ng, Lonneke Verboon, Hasan Issa, Raj Bhayadia, Oriol Alejo, Dorit Borchert, Eniko Regenyi, Dirk Reinhardt, Marie-Laure Yaspo, Dirk Heckl, Jan-Henning Klusmann

Blood (2021) 138 (Supplement 1): 500.

https://doi.org/10.1182/blood-2021-153984

Published: 2021

Journal Articles

Improved Outcome in Pediatric AML - the AML-BFM 2012 Study

Katharina Waack, Markus Schneider, PhD, Christiane Walter, MSc, Ursula Creutzig, MD, Jan-Henning Klusmann, Mareike Rasche, MD, Heidrun Boztug, Katharina Jansen, PhD, Gabriele Escherich, MD, Michael Frühwald, MD, Michael Dworzak, MD PhD, Dirk Reinhardt, MD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-139189

Published: 2020

Journal Articles

Characterization of a Novel JAK1 Pseudokinase Mutation in the First Case of Trisomy 21-Independent GATA1-Mutated Transient Abnormal Myelopoiesis

Julius Lukes, Jr., MD, Petr Danek, MSc, Oriol Alejo, Eliska Potuckova, Ondrej Gahura, Dirk Heckl, PhD, Julia Starkova, PhD, Jan Zuna, Jan Stary, Prof., MD PhD, Jan Trka, Prof., MD PhD, Jan-Henning Klusmann, Marketa Zaliova, MD PhD

Blood (2019) 134 (Supplement_1): 4208.

https://doi.org/10.1182/blood-2019-122168

Published: 2019

Journal Articles

MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 2627.

https://doi.org/10.1182/blood-2018-99-116256

Published: 2018

Journal Articles

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Blood (2018) 132 (Supplement 1): 543.

https://doi.org/10.1182/blood-2018-99-116661

Published: 2018

Journal Articles

Identification of Novel Lncrnas That Predict Survival in AML Patients and Modulate Leukemic Cells

Sarah Grasedieck, MSc, Christoph Rueß, MSc, Nicole Pochert, MSc, Susanne Lux, MSc, Adrian Schwarzer, MD PhD, Jan-Henning Klusmann, Mojca Jongen-Lavrencic, MD PhD, Jonathan R. Pollack, MD PhD, Arefeh Rouhi, PhD, Florian Kuchenbauer, MD PhD

Blood (2018) 132 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2018-99-118331

Published: 2018

Journal Articles

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial

Madita Uffmann, Mareike Rasche, Martin Zimmermann, Christine von Neuhoff, Ursula Creutzig, Michael Dworzak, Lenie Scheffers, Henrik Hasle, C. Michel Zwaan, Dirk Reinhardt, Jan-Henning Klusmann

Blood (2017) 129 (25): 3314–3321.

https://doi.org/10.1182/blood-2017-01-765057

Published: 2017

Includes: Supplemental data

Journal Articles

The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia

Blood (2016) 128 (22): 1534.

https://doi.org/10.1182/blood.V128.22.1534.1534

Published: 2016

Journal Articles

Successes and Challenges of Pediatric AML: A Report on Survival, Salvage Therapy and Causes of Deaths in the AML-BFM Study Group from 1987 -2012

Mareike Rasche, MD, Martin Zimmermann, PhD, Lisa Kellerstrass, Ursula Creutzig, MD PhD, Jan-Henning Klusmann, MD, Dirk Reinhardt, MD PhD

Blood (2016) 128 (22): 450.

https://doi.org/10.1182/blood.V128.22.450.450

Published: 2016

Journal Articles

Crispr-Cas9 Induced MLL-Rearrangements Cause Clonal Outgrowth in CD34+ Hematopoietic Stem Cells

Jana Reimer, Sabine Knoess, Maurice Labuhn, Emmanuelle Marie Charpentier, PhD, Jan-Henning Klusmann, MD, Dirk Heckl, PhD

Blood (2015) 126 (23): 165.

https://doi.org/10.1182/blood.V126.23.165.165

Published: 2015

Journal Articles

The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia

Blood (2015) 126 (23): 1244.

https://doi.org/10.1182/blood.V126.23.1244.1244

Published: 2015

Journal Articles

Members of the Mir-99/100~125 Tricistrons Cooperatively Induce a Pre-Leukemic Myeloproliferative Disorder

Stephan Emmrich, PhD, Sarva Keihani, Msc, Dirk Reinhardt, MD, Jan-Henning Klusmann, MD

Blood (2015) 126 (23): 3579.

https://doi.org/10.1182/blood.V126.23.3579.3579

Published: 2015

NARROW

MYC-stery of Down syndrome unraveled

TRIP13 Is a Fetal-Enriched Therapeutic Target in NUP98-JARID1A + Pediatric Non-Down Syndrome AMKL

Wilms' Tumor 1 Functions As a Tumor Suppressor to Suppress FLT3-STAT Signaling and Epigenetic Remodeling in Acute Myeloid Leukemia (CALGB 8461, 9665 and 20202; Alliance)

Double trouble: IRAK1/4 inhibitors in AML/MDS

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

Myeloid Leukemia Dependencies at CTCF-Enriched Long Noncoding RNA Loci

Improved Outcome in Pediatric AML - the AML-BFM 2012 Study

Characterization of a Novel JAK1 Pseudokinase Mutation in the First Case of Trisomy 21-Independent GATA1-Mutated Transient Abnormal Myelopoiesis

MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia

Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome

Identification of Novel Lncrnas That Predict Survival in AML Patients and Modulate Leukemic Cells

Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial

The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia

Successes and Challenges of Pediatric AML: A Report on Survival, Salvage Therapy and Causes of Deaths in the AML-BFM Study Group from 1987 -2012

Crispr-Cas9 Induced MLL-Rearrangements Cause Clonal Outgrowth in CD34+ Hematopoietic Stem Cells

The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia

Members of the Mir-99/100~125 Tricistrons Cooperatively Induce a Pre-Leukemic Myeloproliferative Disorder

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only